Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Small Biopharmas Should Be Wary Of Early Results – US FDA Official

Executive Summary

Two former Genzyme execs, one of whom now works at CDER, warn small companies to avoid over-emphasizing results from early, uncontrolled trials in their planning and business decision-making.


Related Content

Carrots and Stick: Biopharma At The White House
No More Sarepta-Like Development, FDA Officials Say
Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
Sarepta's Eteplirsen Approved After Contentious Internal Debate
CDER Taps Genzyme Exec As Deputy Director For Science Operations


Related Companies